Search Results

Palifermin

Palifermin is FDA approved to help prevent or lessen severe oral mucositis (inflammation of the mucous membrane of the mouth) in patients receiving certain types of blood cancer therapy.

Pamidronate

Thank You to Our Extraordinary LLS Volunteers

You may have driven an important project to the finish line or reached a new fundraising goal. Perhaps you comforted someone in need, greeted families with a warm smile or raised your voice to influence change. I hope we get the opportunity to meet one day (if we haven’t already), but until then: our heartfelt thanks go out to you, our incredible volunteers.

You are at the heart of our quest to find cancer cures, and our gratitude to you runs deep because you are truly the driving force behind our mission.

Tile under microscope

Clinical Trials: Why They Matter and How to Make Them More Accessible

Cancer treatments can be lifesaving. As an organization, The Leukemia & Lymphoma Society (LLS) has invested more than $1.7 billion in blood cancer research since its inception in 1949—all with the hope that this research leads to scientific breakthroughs that improve and save lives. 

But to make sure this research leads to safe and innovative treatments, we have to thoroughly test it.  

"We did it" text with confetti

How LLS and Advocates Helped Secure Landmark Health Reforms

Born with leukemia, Eevie beats the odds and turns five!

After Eevie was born, she was diagnosed with a rare form of childhood blood cancer that affects 1 in 5 million newborns. Doctors gave her a 17 percent chance of surviving to age 2. This month, Eevie celebrates her fifth birthday. Each year her mother Brynne has shared her progress on this blog (you can read those stories here).

Is a Clinical Trial Right For You?

Because it can take up to 15 years for a new blood cancer drug to be studied and made available for doctors to prescribe, some patients opt for clinical trials as a way to gain early access to a promising treatment. Advancing new cancer therapies requires years of extensive clinical investigation, but clinical trials come with no guarantees. "A drug is allowed to enter the clinical trial phase based on scientific evidence including cell and animal studies, but it's still considered experimental and unproven.

Kendra stands against a stone wall, wearing a pink shirt, hiking gear, and a hat.

The hills I have climbed

Beat AML in the Time of COVID-19: A Powerful New Video

Like many clinical trials across the U.S. and the globe, The Leukemia & Lymphoma’s Beat AML Master Trial has been dramatically impacted by the COVID-19 pandemic and has had to make adjustments to continue to provide critical treatment to patients who were previously enrolled.

A Groundbreaking Trial

Defining PIK3R5-related PI3K gamma dependency as a novel therapeutic target in blood cancers including BPDCN

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive blood cancer without adequate treatment. In a genome-wide CRISPR interference screen, BPDCN was highly dependent on the PI3Kγ pathway and specifically the PIK3R5 adaptor subunit. A subset of leukemias may share this vulnerability. We will interrogate the mechanism of this unique dependency and integrate PIK3R5/PI3Kγ targeting with leukemia therapy. Our goal is to provide novel treatments for PIK3R5-dependent malignancies.

Filgrastim-sndz

Filgrastim-sndz is FDA approved as a biosimilar to US-licensed Neupogen® for the five indications for which Neupogen is approved:

  • Patients with cancer receiving myelosuppressive chemotherapy;
  • Patients with acute myeloid leukemia receiving induction or consolidation chemotherapy;
  • Patients with cancer undergoing bone marrow transplantation;
  • Patients undergoing autologous peripheral blood progenitor cell collection and therapy; and
  • Patients with severe chronic neutropenia.

Against All Odds, Eevie Turns 1!

A first birthday is always a big occasion, but for Eevie, it's taken on a whole new meaning. She was born with a rare leukemia that gives her a 17 percent chance of surviving to age 2. Even her parents weren't sure she would make it this far. "We didn't think she would still be here. The odds were never in her favor," said her mom, Brynne. Eevie was born with congenital acute lymphoblastic leukemia (ALL), an extremely rare condition affecting 1 in 5 million newborns.

Hundreds to Climb Iconic Bank of America Tower to End Blood Cancer

FDA Approves Targeted Treatment for Rare, Aggressive form of Blood Cancer

Shred For Red: An Unstoppable Community Hits the Slopes to End Blood Cancer

NCI Genetic Epidemiology Branch- Familial Blood and Lymph Node Cancers

To study families with multiple cases of lymphoproliferative disorders.

  • The National Cancer Institute (NCI) of the National Institutes of Health (NIH) is studying the causes of familial blood and lymph node cancers. The primary focus is on: Chronic lymphocytic leukemia (CLL), Hodgkin Lymphoma (HL), Non-Hodgkin Lymphoma (NHL), Waldenstrom’s macroglobulinemia (WM), and Multiple myeloma (MM).
  • The clinical evaluation includes a medical history and physical examination and may also entail disease-related laboratory or imaging studies. In certain cases, patients may be invited to visit the NIH Warren G. Magnuson Clinical Center in Bethesda, Maryland, for evaluation. Otherwise, study components can often be completed in or near the patient's home community.
     

Families with 2 or more living individuals in the family with a history of the same lymphoproliferative disorder

800-518-8474 https://dceg.cancer.gov/research/clinical-studies/blood-lymph-cancers

Love, Strength, Support: Sibling care in pediatric blood cancer journeys

Coping with Childhood Blood Cancer: The Power of Play and Creative Therapies for Families

Blood Cancer Patients Need Support Now More Than Ever

Closer to a Cure Inspires & Educates About Treatment Advances of Blood Cancers

FDA Approval of New Precision Medicine Therapy for Deadly Blood Cancer

Burlington Stores and LLS Bring Smiles to Those Touched by Blood Cancers

Optimizing Clinical Outcomes in Blood Cancers through Groundbreaking Translational Research

LLS Announces Expansion of Precision Medicine Approach to Fight Blood Cancer

FDA Approval of AML Therapy is a Significant Advance for Blood Cancer Patients